Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy

被引:9
|
作者
El Beshlawy, Amal [1 ]
Murugesan, Vagishwari [2 ]
Mistry, Pramod Kumar [3 ]
Eid, Khaled [1 ]
机构
[1] Cairo Univ, Dept Pediat, Pediat Hematol, Giza, Egypt
[2] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA
[3] Yale Univ, Internal Med & Pediat, Sch Med, 333 Cedar St,LMP 1080,POB 208019, New Haven, CT 06520 USA
关键词
Gaucher disease; Hepatopulmonary syndrome; Enzyme replacement therapy; Pulmonary complications; PULMONARY-HYPERTENSION; PHENOTYPE; DETERMINANTS; ASSOCIATION; CELLS;
D O I
10.1016/j.ymgmr.2019.100490
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Advanced liver disease complicated by hepatopulmonary syndrome is a recognized complication of Gaucher disease. Macrophage-targeted, recombinant enzyme replacement therapy is effective in reversing clinical manifestations attributed to the accumulation of glycolipid-laden macrophages but it is not known whether advanced fibrotic features of the disease can be ameliorated. We describe a splenectomized patient with Gaucher disease who developed massive hepatomegaly, cirrhosis of the liver and life-threatening hepatopulmonary syndrome. Treatment with Imiglucerase enzyme replacement therapy resulted in dramatic reversal of hepatopulmonary syndrome and liver disease. Our report suggests that Gaucher disease pathology involving advanced fibrosis and life-threatening complications can be reversed by imiglucerase enzyme therapy. Synopsis: Effect of imiglucerase enzyme replacement therapy on Hepatopulmonary Syndrome in Gaucher Disease.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Effect of enzyme replacement therapy with imiglucerase (Cerezyme.) every 4 weeks in patients with type I Gaucher disease
    Weinreb, Neal
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S41 - S41
  • [32] Recombinant Glucocerebrosidase (Imiglucerase) as a Therapy for Gaucher Disease
    Gregory M. Pastores
    BioDrugs, 2010, 24 : 41 - 47
  • [33] Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease (vol 88, pg 179, 2013)
    Ben Turkia, Hadhami
    Gonzalez, Derlis
    Barton, Norman
    Zimran, Ari
    Kabra, Madhulika
    Lukina, Elena
    Giraldo, Pilar
    Kisinovsky, Isaac
    Bavdekar, Ashish
    Ben Dridi, Marie-Francois
    Gupta, Neerja
    Kishnani, Priya
    Sureshkumar, E. K.
    Wang, Nan
    Crombez, Eric
    Bhirangi, Kiran
    Mehta, Atul
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (07) : 632 - 632
  • [34] Hepatopulmonary syndrome: Use of extracorporeal life support for life-threatening hypoxia following liver transplantation
    Fleming, Geoffrey M.
    Cornell, Timothy T.
    Welling, Theodore H.
    Magee, John C.
    Annich, Gail M.
    LIVER TRANSPLANTATION, 2008, 14 (07) : 966 - 970
  • [35] The HELLP Syndrome - A life-threatening and postpartum Disease
    Hungbaur, Simone
    Bahlmann, Franz
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (09) : 843 - 845
  • [36] Reversal of warfarin in life-threatening bleeding
    Ng, Daniel S. K.
    HONG KONG MEDICAL JOURNAL, 2015, 21 (02) : 191 - 191
  • [37] Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
    Mistry, Pramod K.
    Batista, Julie L.
    Andersson, Hans C.
    Balwani, Manisha
    Burrow, Thomas Andrew
    Charrow, Joel
    Kaplan, Paige
    Khan, Aneal
    Kishnani, Priya S.
    Kolodny, Edwin H.
    Rosenbloom, Barry
    Scott, C. Ronald
    Weinreb, Neal
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (09) : 929 - 939
  • [38] Enzyme replacement and gene therapy for Gaucher's disease
    Brady, RO
    Barton, NW
    LIPIDS, 1996, 31 : S137 - S139
  • [39] Gaucher disease and enzyme replacement therapy, Iranian experience
    Zaman, T.
    Roya, M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 46 - 46